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ABSTRACT 
Aims: The study objectives were to examine trends in prescription opioid (PO) injection and to 
assess its association with HCV seroconversion among injection drug users (IDUs), accounting 
for other risk factors.  
Design and Setting: A prospective cohort study of IDUs was carried out between 2004 and 2009 
in Montreal, Canada.  
Participants and Measurements: 246 HCV-negative IDUs were included in this analysis. Semi-
annual visits included HCV antibody testing and an interview-administered questionnaire 
assessing risk behaviours. HCV incidence rate was calculated using the person-time method. 
Time-updated Cox regression models were conducted to examine predictors of HCV incidence. 
Findings: The proportion of IDUs reporting PO injection increased from 21% to 75% between 
2004 and 2009 (p < 0.001). Of the 246 participants (81.6% male; mean age 34.5 years; mean 
follow-up time 23 months), 83 seroconverted to HCV (incidence rate: 17.9 per 100 person-years; 
95% CI 14.3, 22.1). PO injectors were more likely to become infected if they did not use 
injection heroin (Adjusted Hazard Ratio (AHR): 2.9 (95% CI: 1.5, 5.5)), whereas the association 
was not statistically significant for participants who reported using both drugs (AHR: 1.2 
(95%CI: 0.6, 2.3). Other independent predictors of HCV incidence were: cocaine injection, 
recent incarceration, and > 30 injections per month.  
Conclusion: PO injection has increased rapidly in recent years, and appears to be an important 
risk factor for HCV acquisition.  Our results suggest that the risks related to PO injection may be 
conditioned by specific drug practices which differ from those of heroin users. 
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INTRODUCTION 
For nearly 20 years, consumption of opioid analgesics has increased in several parts of the world, 
with highest frequencies being reported in North-America, Europe and Oceania (1). The growing 
availability of these analgesics has been accompanied by an increase in prescription opioid (PO) 
misuse. Not surprisingly, the percentage of patients admitted to detoxification units for abuse of 
opioids other than heroin in the United States has quintupled from 1% in 1997 to 5% in 2007 (2). 
In Ontario, Canada, the proportion of new admissions for substance abuse related PO injection 
increased from 10.6% in 2004-2005 to 17.4% in 2009-2010 (3) . 
 
This upward trend was also observed among North-American street-based drug users. In New 
York, the prevalence of PO recreational use was observed among 32% of 586 street-based users 
(4). In Miami, Florida, 12% of 588 drug-involved, street-based sex workers surveyed reported 
having used PO without a legitimate prescription (5). To our knowledge, only two Canadian 
studies have examined PO misuse among street-based drug users. A study conducted among 
regular opiate users between 2001 and 2005 revealed that in five out of seven cities in the 
country, POs, not heroin, was the major form of illicit opioid drug in use (6). In Montreal, a 
recent study showed that 40.6% of street-based regular cocaine users were using illicit POs (7). 
 
Studies conducted in diverse settings have also examined the use of POs by injection. In 
Australia, 46% of injection drug users (IDUs) reported having used morphine in the previous six 
months, with significant variations across states and up to a prevalence of 85% in the northern 
territories (8). In a study conducted in rural Kentucky among non-medical PO users, 35.3% 
reported having injected POs in their lifetime (9). In Quebec, Canada, the prevalence of PO 
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injection, specifically hydromorphone tablets, increased from 27.4% to 41.8% among street-drug 
users recruited between 2003 and 2007 through SurvIDU (a provincial epidemiologic 
surveillance network targeting active injectors recruited mainly through syringe access 
programs) (10).  
 
The recent increase in the use of illicit POs and the growing evidence of intravenous 
administration by a significant number of users is worrisome. IDUs are the population most at 
risk for hepatitis C virus (HCV) transmission in the developed world (11). In countries such as 
the USA, Canada and Australia, where the highest seroprevalence is among middle-aged people, 
injection drug use accounts for 68% to 80% of current infections (12-15). 
 
There is little evidence indicating how PO injection might be associated with HCV infection. 
Among IDUs, syringe sharing is the strongest determinant of HCV seroconversion (16). Sharing 
is highly correlated with behaviours driven by specific drug use patterns.  The intermediate steps 
required in the process of drug preparation and apportioning (17), that may include communal 
use or sharing of injection paraphernalia (cookers, filters and water), increase the risk for HCV 
infection (18-20).  According to recent ethnographic work, POs have to be crushed, dissolved 
and filtered before being injected, yielding opportunities for HCV transmission between injection 
partners (21).  
 
The present study was conducted in a population of active drug users recruited and followed 
longitudinally between 2004 and 2009 in Montreal, Canada. The objectives of the study were 
twofold: i) to examine trends in the types of drugs used at the time of recruitment, with a specific 
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focus on POs, and ii) to assess the association between PO injection use and HCV 
seroconversion among IDUs. We specifically tested whether the incidence of HCV would be 
associated with PO injection, after adjusting for other covariates. 
 
MATERIAL AND METHODS 
Study population: 
The study population was drawn from the St. Luc Cohort, an open cohort of current IDUs 
established in Montreal in 1988 to study determinants of Human Immunodeficiency Virus (HIV) 
transmission (22). To be eligible, participants had to be current IDUs (i.e., as having injected 
drugs within the previous six month) and be 18 years of age or older.  
 
In November, 2004, the cohort’s objectives were expanded and a new cohort was assembled to 
examine individual and contextual factors associated with HCV and HIV infections among 
current IDUs.. Eligible HCV-negative IDUs already enrolled in the former cohort were invited to 
participate in the new HCV incidence studies (n=101). New participants (n=210) were recruited 
in a manner consistent with previous strategies, and using the same eligibility criteria. A detailed 
description of the recruitment and follow-up procedures has been previously published (23). The 
sample population included HCV-negative participants recruited from the former cohort (32%), 
as well as new participants recruited through street-level strategies such as word-of-mouth (34%) 
or through community program referrals (34%). All participants signed an informed consent in 
compliance with institutional review board regulations of the Centre hospitalier de l’Université 
de Montréal. Cohort visits were scheduled at six-months intervals and consisted of behavioural 
questionnaires administered by trained interviewers and venous blood samples drawn for HIV 
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and HCV antibody testing.  Participants were asked to return for their serostatus test results two 
weeks after their visits, at which time post-test counselling and referrals were provided. All 
participants received a CAD $15.00 stipend at each visit to compensate them for their time. 
 
Of the overall sample (n= 311), 246 participants (79%), HCV-seronegative at enrolment, were 
followed up at least once between November 2004 and December 2009, and were included in the 
incidence analysis.  All seroconverters had a documented negative HCV antibody test at the time 
of enrolment and a subsequent positive HCV antibody test during a follow-up visit.   
 
Measures: 
The main outcome variable was HCV infection detected by the presence of HCV antibodies. A 
positive HCV antibody test was determined by enzyme immunoassay assay (Abbott 
Laboratories) and confirmed by RT-PCR (Roche Diagnostic Systems).  Specimens with 
indeterminate results were sent for confirmatory tests by dual EIA and/or RIBA (gold standard). 
Socio-demographic characteristics (age, gender, education, housing arrangement), drug use 
patterns, and injection behaviours were examined according to PO injection use and as potential 
determinants of HCV seroconversion. Higher education was defined as having completed a 
college degree. Consistent with previous studies, the idiom “unstable housing arrangement” was 
defined as living on the street, in shelters, or in apartment-hotels rented on a monthly basis 
(indicating a rapid turnover compared to typical 12-month rent-lease accommodation standards 
in Montreal) (24). Drug-use patterns and injection behaviours were assessed by questioning 
participants on the type of drugs used, modes of administration and sharing practices regarding 
syringes or other injection paraphernalia in the past 6 months. For example, participants were 
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asked whether they used illicit POs, heroin, cocaine or crack through snorting, smoking or 
injecting. A list of known commercial and street denominations helped distinguish between the 
varieties of substances in circulation. The terms “injection paraphernalia” were said to 
encompass the drug preparation container, water or dilution liquid and filter or cotton.   
 
Statistical Analyses: 
Cochran-Armitage trend tests were conducted to compare types of drugs used over the five-year 
period. Descriptive analyses were used to compare IDU characteristics according to PO injection 
use. Kaplan–Meier technique was used to estimate the survival function (25). Cox proportional 
hazards regression was used to estimate crude and adjusted Hazard ratios (HR), and 
corresponding 95% Confidence Interval (CI) to examine the relations between PO injection use 
and incidence of HCV. Following the purposeful selection procedure (26), significant variables 
at the 5% level as well as those that showed a confounding effect on significant covariates (that 
is, those that changed a significant variable’s coefficient by more than 20%) were retained in the 
final multivariate models. In addition, age and gender were retained in the final model.  
 
To investigate whether the effects of particular risk factors on the hazard of HCV seroconversion 
varied according to PO injection use, Cox regression analyses tested two-way interactions with 
relevant risk factors. In the case of a significant interaction, we estimated separate hazard ratios 
for the associations between a corresponding factor and HCV incidence in each of the two PO 
injection groups. Individual exposure measures, except gender and age, were modelled as time-
dependent covariates representing their most recent values. A covariate “recruitment scheme” 
was included in analyses to account for the differential cohort participation duration and the 
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potential influence of serial HCV counselling and testing on behaviours and transmission 
between participants recruited from the former cohort membership and those recruited from 
street-level and community-based strategies.    
 
For all hypothesis testing, p<0.05 for the 2-tailed Wald test was used as the criterion for 
statistical significance. All analyses were conducted using SAS® v 9.2. 
 
RESULTS 
Of the 1,042 cohort participants recruited (HIV and/or HCV-negative active IDUs) between 
November, 2004 and December, 2009, 731 (70%) had HCV antibodies.  Of the 311 HCV-
negative cohort members eligible for this investigation, 246 (79%) were followed up at least 
once and were included in the incidence analyses. The majority was male (81.6%), with a mean 
age of 34.5 years (SD=9.2). The average duration of injection-drug use was 9.9 years (SD 8.4).   
 
Figure 1 shows the trends in IDU proportions for each drug of interest by year of enrolment. 
Increasing trends were observed for PO and heroin injection use. The proportion of IDUs 
reporting PO injection use more than tripled between 2005 and 2009, from 21% to 75%. When 
including only the 210 participants who were recruited from street-level and community-based 
strategies, PO injection use increased significantly, i.e., from 42.4% in 2004-2005 to 75% in 
2009 (p-value for trend test= 0.002), while cocaine injection, heroin injection and crack use 
remained stable.  
 
 
10 
Table 1 compares baseline characteristics of the 246 participants included in incidence analyses 
according to PO injection use. Compared to non-users, PO injection users were younger, more 
likely to report heroin injection, and to have been recruited from street-level and community-
based strategies. They were also more likely to report high-risk injection behaviours (including 
sharing syringes, frequent injections and injection in public places) and to have recently been 
incarcerated.    
 
Prior to seroconversion, participants contributed a total of 463 person-years of observation. The 
mean follow-up time was 23 months (SD 16.7) and the median time between consecutive visits 
was 5.9 months. A total of 83 individuals (33.7%) seroconverted to HCV, for an incidence rate 
(IR) of 17.9 per 100 person-years (95% confidence interval (CI): 14.3, 22.1).  
 
Table 2 provides crude associations between socio-demographic and behavioural characteristics 
and the risk of HCV seroconversion. Injecting POs was associated with a 3.2 fold increased risk 
of HCV acquisition, whereas the association with heroin injection did not reach statistical 
significance. Injecting cocaine was associated with an increased risk of HCV seroconversion. In 
addition, several injection-related practices were associated with an increased risk of HCV 
infection; for example, the sharing of syringes or other paraphernalia, injection frequency and 
injection in public places. IDUs reporting unstable housing arrangements or recent incarceration 
were also more likely to seroconvert to HCV, as were IDUs recruited through street-level and 
community-based strategies, compared to those recruited among members of the former cohort.   
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Results from the Cox’s multivariable model are presented in Table 3. We found only one 
marginally statistically significant interaction between PO injection use and heroin injection use. 
PO injectors were three times more likely to become infected if they did not use IV heroin (HR: 
2.88 (95% CI: 1. 52, 5.45)), whereas the association was not statistically significant for 
participants who reported using both drugs (HR: 1.19 (95% CI: 0.61, 2.30); p value for 
interaction term: 0.05). Other variables significantly associated with an increased risk of HCV 
acquisition included IV cocaine use, frequency of injection and recent incarceration. In the 
multivariate model, the effect of sharing syringes or paraphernalia and of the recruitment scheme 
were deemed non significant.  
 
DISCUSSION 
Our results confirm a significant increase in the prevalence of PO injection among HCV-
negative IDUs in Montreal between 2005 and 2009. Younger IDUs, and those recruited outside 
of the cohort assembled by the end of 2004, were more likely to report PO injection, suggesting 
the emergence of PO injection among IDUs at an early stage of their injectors’ drug-use 
trajectory.  
 
In Australia and Vancouver, Canada, a reduction of heroin availability was implicated in 
significant shifts in drug-use patterns and possibly in increased drug-related harms (8, 27-29). In 
Estonia, a shift in use from heroin to POs was observed following heroin shortages in 2001(30). 
In our study, we did not find a concomitant reduction in heroin injection that could partially 
account for the observed PO use increase. Rather, recent ethnographic data has shown that easy 
access, through independent operators and without the need for personal contacts, as well as low 
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prices, are likely at the root of this emerging illicit market (21). 
 
Evidence of health risks associated with PO injection is relatively scarce. In Australia, recent 
morphine injectors were more likely to report morphine dependence (38%), difficulty finding 
veins into which to inject (36%), as well as scarring and bruising (27%) (8). To our knowledge, 
our study is the first to examine PO injection in relation to HCV transmission. Of concern, we 
observed that HCV-negative PO injectors were more likely to report high-risk injection practices 
associated with HCV seroconversion in previous studies, such as high injection frequency (31, 
32), sharing of used syringes (16, 33) and injection in public places (34) when compared to non 
PO injectors. In multivariate analyses, PO injectors who did not report heroin injection were 
three times more likely to acquire HCV infection relative to non PO injectors, after controlling 
for other high-risk behaviours. . Interestingly, PO injectors who were also reporting heroin use 
were not at higher risk of seroconverting when compared to those who did not report PO 
injection.   
 
Consistent with previous study findings in Canada and in Australia (27, 31, 32, 35), cocaine 
injection was an independent risk factor for HCV transmission. Injection cocaine use was not 
associated with PO use, and did not explain the relation between HCV seroconversion and PO 
use among non-heroin users. Imprisonment in the past six months was independently associated 
with higher HCV incidence. It has been demonstrated that having injected while in prison 
predicts HIV and HCV infections (36). Of the 57 participants who reported a recent 
imprisonment during the study period, only 3 reported having injected drugs while in prison. One 
of these individuals did seroconvert to HCV, an event which occurred more than 18 months after 
13 
being released. Besides the documented risk associated with injection drug use while in prison, 
heightened vulnerability may play an important role in increasing high-risk injection behaviours 
and HCV acquisition after release (37). 
 
Contrary to our primary hypothesis, the sharing of syringes or other injection paraphernalia did 
not predict HCV transmission, after accounting for other covariates.  While several studies have 
reported associations between HCV seroconversion and syringe sharing, many associations were 
relatively weak after controlling for other factors; other studies failed to find any association (38-
41). Sharing is highly correlated with behaviours driven by specific drug use patterns. This has 
been mainly documented among cocaine users, whose consumption is often characterized as 
bursts of high intensity use or ‘drug runs’, which in turn induce sharing and higher risks of 
infection (42). Unmeasured drug-use patterns, combined with the possible under-reporting of 
syringe or paraphernalia sharing while intoxicated, have been offered as an explanation for the 
preponderance of cocaine as an independent predictor of HIV infection over sharing behaviours 
(42-44). Possibly, the independent association between PO injection and HCV seroconversion 
observed in our study proceeds from an analogous paradigm. 
 
Recent ethnographic observations carried out in downtown Montreal have shown that the 
logistical aspects of the PO preparation process, coupled with indigent social practices, may 
increase the risk of infection (21). Some PO formats require large amounts of water in order to 
be dissolved. Given that the largest syringe distributed (1cc) cannot hold the entire dissolved 
solution, users have to inject themselves more than once. Consequently, the cup and filter may 
become contaminated as a result of the same syringe being used for repeated injections. 
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Furthermore, PO preparation for injection produces residue that adheres to the cup and the filter. 
This residue, known as “wash”, may contain enough opioid substance to produce a minimal 
effect or to stem withdrawal symptoms; thus it is usually kept for ulterior use. What becomes 
worrisome is that a potentially contaminated “wash” could be given to another user. “Washes” 
have an economic value and are one of the goods that are exchanged or given among street-based 
users. These “washes” play an important role in the moral economy of “gift-giving” among 
Montreal street-based users (45, 46). Ethnographic observation suggests that “wash” giving and 
exchanging is not necessarily equated with ancillary paraphernalia sharing, since “washes” are 
considered independent drugs capable of producing a high or countering withdrawal symptoms, 
a factor which may have contributed to the under-reporting of injection equipment sharing.  
 
The present study presents a number of limitations: Participants were not randomly selected; 
hence our sample cannot be considered an adequate representation of the Montreal IDU 
population as a whole. The sample is over-represented in terms of males and chronic cocaine 
IDUs, compared to Quebec provincial data on IDUs (47). The study was conducted in a large 
cosmopolitan North-American city, facing a rising PO injection use epidemic. As such, it may 
serve as a valid representation of PO injection  misuse relevant to IDUs elsewhere.    
 
Even though our follow-up rates were high for a drug-using population, our data may have been 
influenced by losses to follow-up. Because of the risk of “socially desirable” responses, the study 
of illicit drug use and related behaviours is problematic; especially as the study progresses and 
bonds evolve between participants and staff. Although there is some published evidence to 
suggest that drug users do provide reliable and valid responses, the risk of bias if it exists, is 
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more likely to go unreported (48). In addition, we did not include the “wash” as a specific item in 
our definition of injection paraphernalia, allowing only for indirect evidence of its potential role 
as a driver of HCV transmission among PO users. 
 
As for other cohort studies, a lead-time bias exists wherein potentially important risk-behaviour 
events, which may have occurred prior to participants joining the cohort, could not be measured 
or accounted for; hence, residual confounding of our results is a possibility. 
 
This study clearly illustrates the rising prevalence of PO injection use among Montreal IDUs. 
While many have hypothesized that PO injection use is involved with numerous risky behaviours 
related to blood-borne pathogen transmission, we have shown for the first time that PO injection 
actually is an independent predictor of HCV transmission. Aside from well-documented 
individual risk-behaviours, our results suggest that risks related to PO injections may be 
conditioned by specific drug practices and contexts prevailing outside of the traditional networks 
of heroin IDUs.  To act on such a complex phenomenon will thus require innovative strategies. 
Current approaches such as increasing the coverage of syringe through comprehensive exchange 
and distribution services, and providing drug treatment, may be only part of the solution.  These 
results underscore the need for a better understanding of the processes and contexts associated 
with PO injection use will lead to new and more comprehensive prevention and intervention 
strategies. 
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FIGURE 1 
 
Legend: 
P-values by Cochran-Armitage trend tests:  Prescription opioid injection:  < 0.001; Cocaine 
injection = 0.01; Heroin injection = 0.01; Crack use = 0.05. 
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Table 1 :  Baseline Characteristics of 246 HCV initially antibody-negative injection drug users, according to their prescription opioid injection use, 
recruited between November 2004 and December 2009 in the St. Luc Cohort, Montreal, Quebec, Canada. 
Variable 
 
 
 
Total 
n=246 
% (SD) 
Prescription 
Opioid injection 
n=80 
% (SD) 
No Prescription 
Opioid injection 
n=166 
% (SD) P-Value* 
Less than 30 YOA 38.6 (3.1) 53.7 (5.6) 31.3 (3.6) <0.001 
Male gender 81.6 (2.5) 81.2 (4.4) 81.8 (3.0) 0.914 
College education or higher 13.4 (2.2) 13.7 (3.9) 13.2 (2.6) 0.915 
Unstable housing arrangements 
past 6 months 36.6 (3.1) 42.5 (5.5) 33.7 (3.7) 0.181 
> 30 injections past month 52.9 (3.2) 80.0 (4.5) 39.8 (3.8) <0.001 
Heroin injection past 6 months 43.5 (3.2) 57.5 (5.5) 36.7 (3.7) 0.002 
Cocaine injection past 6 
months 69.1 (3.0) 75.0 (4.8) 66.3 (3.7) 0.165 
Crack use past 6 months 65.8 (3.0) 68.7 (5.2) 64.5 (3.7) 0.506 
Sharing syringe past 6 months 28.5 (2.9) 42.5 (5.5) 21.7 (3.2) <0.001 
Sharing injection paraphernalia 39.4 (3.1) 47.5 (5.6) 35.5 (3.7) 0.072 
Incarcerated past 6 months 23.2 (2.7) 33.7 (5.3) 18.1 (3.0) 0.006 
27 
Injecting in public places past 
6 months 48.4 (3.2) 72.5 (5.0) 36.7 (3.7) <0.001 
Recruited  through street-level 
and community-based 
strategies (vs. former cohort) 67.5 (3.0) 93.7 (2.7) 54.8 (3.9) <0.001 
* : P-values by chi-squared test.  
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Table 2 : Unadjusted estimated relative hazard of hepatitis C virus (HCV) seroconversion according to socio-demographic and 
behavioural factors for 246 initially HCV-negative injection drug users participating in a prospective cohort in Montreal, Canada, 
between November 2004 and December 2009. 
 
Variable 
N 
seroconversions
Person-time Incidence rate 95% 
Confidence 
Interval Hazard Ratio 
95% 
Confidence 
Interval 
Less than 30 YOA 
No  
Yes 
 
47 
36 
 
281.07 
156.49 
 
16.72 
23.00 
 
12.44, 22.03 
16.38, 31.48 
1 
1.32 0.86, 2.05 
Female Gender 
No 
Yes 
 
71 
12 
 
346.45 
  89.22 
 
20.49 
13.45 
 
16.13, 25.69 
 7.29, 22.86 
1 
0.70 0.38, 1.29 
College education or 
higher 
No 
Yes  
 
 
77 
 6 
 
 
370.31 
 67.25 
 
 
20.79 
  8.92 
 
 
16.53, 25.84 
 3.62, 18.56 
1 
0.46 0.20, 1.05 
29 
Unstable housing 
arrangements past 6 
months 
No 
Yes 
 
 
 
50 
32 
 
 
 
330.97 
105.88 
 
 
 
15.11 
30.22 
 
 
 
11.34, 19.75 
21.06, 42.11 
1 
1.62 1.03, 2.55 
> 30 injections past 
month 
No 
Yes 
 
 
22 
61 
 
 
286.55 
150.58 
 
 
  7.68 
40.51 
 
 
 4.95, 11.41 
31.28, 51.66 
 
1 
4.59 
 
2.80, 7.53 
Prescription opioid 
injection past 6 months 
No 
Yes 
 
 
44 
39 
 
 
358.23 
 79.33 
 
 
12.28 
49.16 
 
 
 9.04, 16.33 
35.49, 66.48 
 
1 
3.20 
 
 
2.06, 4.99 
Heroin injection past 6 
months 
No 
 
 
44 
 
 
277.95 
 
 
15.83 
 
 
11.65, 21.05 
 
 
1 
 
 
 
30 
Yes 39 159.61 24.43 17.64, 33.04 1.40 0.90, 2.16 
Cocaine injection past 6 
months 
No 
Yes 
 
 
 9 
74 
 
 
168.31 
269.25 
 
 
 5.35 
27.48 
 
 
  2.61,    9.81 
21.74, 34.30 
1 
4.63 2.31, 9.27 
Crack use past 6 months 
No 
Yes 
 
36 
47 
 
221.94 
215.61 
 
16.22 
21.80 
 
11.55, 22.20 
16.21, 28.72 
 
1 
1.07 
 
 
0.69, 1.67 
Sharing syringe past 6 
months 
No 
Yes 
 
 
51 
32 
 
 
337.00 
100.56 
 
 
15.13 
31.82 
 
 
11.40, 19.73 
22.17, 44.34 
 
 
1 
1.87 
 
 
 
1.20, 2.92 
Sharing injection 
paraphernalia past 6 
months 
No 
 
 
47 
36 
 
 
309.01 
127.54 
 
 
15.21 
28.23 
 
 
11.31, 20.04 
20.09, 38.62 
1 
1.55 1.00, 2.42 
Yes 
Incarceration past 6 
months 
No 
Yes 
 
 
53 
30 
 
 
361.19 
 76.36 
 
 
14.67 
39.29 
 
 
11.11, 19.04 
27.04, 55.32 
 
1 
2.45 
 
 
1.57, 3.85 
Injection in public places 
past 6 months 
No 
Yes 
 
 
29 
54 
 
 
272.87 
164.69 
 
 
10.63 
32.79 
 
 
 7.27, 15.05 
24.89, 42.44 
 
 
1 
2.67 
 
 
 
1.69, 4.23 
Recruited through street-
level and community-
based strategies (vs. 
former cohort) 
No  
Yes 
 
 
 
 
16 
67 
 
 
 
 
213.41 
224.15 
 
 
 
 
 7.50 
29.89 
 
 
 
 
 4.44, 11.92 
23.36, 37.71 
 
 
 
1 
3.34 
 
 
 
 
1.92, 5.81 
31 
32 
Table 3 : Covariate-adjusted associations between hepatitis C virus (HCV) 
seroconversion and prescription opioid injection among 246 initially HCV-negative 
injection drug users participating in a prospective cohort in Montreal, Canada, between 
November 2004 and December 2009. 
Variable  Adjusted Hazard 
Ratio 
95% Confidence 
Interval 
Less than 30 years of age 
No 
Yes  
 
1 
0.90 
 
 
0.52, 1.56 
Female gender 
No 
Yes 
 
1 
0.90 
 
 
0.46, 1.74 
Interaction between IV illicit prescription opioid use and IV heroin use 
No IV opioid use past 6months  
Prescription opioid injection past 6 months  
and heroin injection past 6 months  
Prescription opioid injection past 6 months  
and no heroin injection IV past 6 months  
 
1 
 
1.19 
 
2.88 
 
 
0.61, 2.30 
 
1.52, 5.45 
Cocaine injection past 6 months 
No 
Yes 
 
1 
3.00 
 
 
1.44, 6.24 
Sharing syringe past 6 months   
33 
No 
Yes 
1 
1.29 
 
0.81, 2.07 
Incarceration past 6 months 
No 
Yes 
 
1 
2.41 
 
 
1.50, 3.89 
Recruited through street-level and community-based 
strategies (vs. former cohort) 
No  
Yes 
 
 
1 
1.71 
 
 
 
0.92, 3.18 
>30 injections past month 
No 
Yes 
 
1 
2.72 
 
 
1.58, 4.70 
 
 
